Pentadeca Arginate (PDA)

The verdict

Our read at a glance.

Whether a differently-salted version of a peptide inherits that peptide's evidence, and whether that evidence supported the claims in the first place.

The signal

Read the source list on this page carefully, because it is the argument. Every reference is about BPC-157: the stable gastric pentadecapeptide, its wound healing and muscle and tendon work, the reviews of its pleiotropic activity, the nitric oxide system relation, and the small number of registered human trials that exist for it, including a hamstring strain study. There is no published study of Pentadeca Arginate. Not a trial, not a pharmacokinetic study, not a comparison against the parent peptide. The claim that it is more stable or more effective has no published support of any kind; it is a marketing assertion attached to a body of rodent literature belonging to a different preparation.

The unknown

Whether it behaves like BPC-157 at all. Changing the counter-ion and formulation of a peptide can change stability, absorption and exposure, which is precisely why the superiority claim is made - and the same reason the parent compound's data cannot simply be inherited. Nobody has measured it.

Our read

This is what regulatory arbitrage looks like in the peptide market. A compound comes under pressure, a renamed variant appears, and the new product borrows the old one's rodent literature while claiming to be better than it - a claim that, by definition, cannot be supported by that literature. The sources here are real and they are all about something else. Until somebody publishes on Pentadeca Arginate, that is the honest description of the evidence.